Этиология, патогенез, факторы риска гиперплазии эндометрия

1. Cree I.A., White V.A., Indave B.I., Lokuhetty D. Revising the WHO classification: female genital tract tumours. Histopathology. 2020ж 76(1): 151-6. doi: 10.1111/his.13977
2. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Гиперплазия эндометрия. M.; 2021. 45 с.
3. Nees L.K., Heublein S., Steinmacher S., Juhasz-Böss I., Brucker S., Tempfer C.B. et al. Endometrial hyperplasia as a risk factor of endometrial cancer. Arch. Gynecol. Obstet. 2022; 306(2): 407-21. https://dx.doi.org/10.1007/s00404-021-06380-5
4. Chou A.J., Bing R.S., Ding D.C. Endometrial atypical hyperplasia and risk of endometrial cancer. Diagnostics (Basel). 2024; 14(22): 2471. https://dx.doi.org/10.3390/diagnostics14222471
5. Wang L., Wei W., Cai M. A review of the risk factors associated with endometrial hyperplasia during perimenopause. Int. J. Womens Health. 2024; 16: 1475-82. https://dx.doi.org/10.2147/IJWH.S481509
6. Свиридова Н.И., Ткаченко Л.В., Яхонтова М.А., Гриценко И.А., Максимов С.Н., Пурясева К.А. Гиперпластические процессы эндометрия: современные подходы к диагностике и лечению. Акушерство, гинекология и репродукция. 2024; 18(1): 83-95.
7. Подзолкова Н.М., Коренная В.В. Современные представления об этиологии, патогенезе и принципах лечения гиперплазии эндометрия. Акушерство и гинекология. 2021; 8: 192-9.
8. Alsudairi H.N., Alrasheed A.T., Dvornyk V. Estrogens and uterine fibroids: an integrated view. Research Results in Biomedicine. 2021; 7(2): 156-63. https://dx.doi.org/10.18413/2658-6533-2021-7-2-0-6
9. Yu K., Huang Z.Y., Xu X.L., Li J., Fu X.W., Deng S.L. Estrogen receptor function: impact on the human endometrium. Front. Endocrinol. (Lausanne). 2022; 13: 827724. https://dx.doi.org/10.3389/fendo.2022.827724
10. Ring K.L., Mills A.M, Modesitt S.C. Endometrial hyperplasia. Obstet. Gynecol. 2022; 140(6): 1061-75. https://dx.doi.org/10.1097/AOG.0000000000004989
11. Cerami L.B., Setti T., Bergamini E., Boselli F. Prediction of endometrial hyperplasia and cancer among premenopausal women with abnormal uterine bleeding. Biomed. Res. Int. 2019; 2019: 8598152. https://dx.doi.org/10.1155/2019/8598152
12. Zhang H., Kong W., Han C., Liu T., Li J., Song D. Correlation of metabolic factors with endometrial atypical hyperplasia and endometrial cancer: development and assessment of a new predictive nomogram. Cancer Manag. Res. 2021; 13: 7937-49. https://dx.doi.org/10.2147/CMAR.S335924
13. Alizadeh Garna S., Yazdani S., Musavi H., Ranaei M., Hajian K., Bouzari Z. Predictive value of body mass index (BMI) and determination of optimum cut-off point in the diagnosis of endometrial hyperplasia in pre-menopausal women with abnormal uterine bleeding. Caspian J. Intern. Med. 2024; 15(1): 87-95. https://dx.doi.org/10.22088/cjim.15.1.9
14. Shetty C., Rizvi S.M.H.A., Sharaf J., Williams K.D., Tariq M., Acharekar M.V. et al. Risk of Gynecological cancers in women with polycystic ovary syndrome and the pathophysiology of association. Cureus. 2023; 15(4): e37266. https://dx.doi.org/10.7759/cureus.37266
15. Пасенов К.Н. Особенности ассоциаций SHBG-связанных генов с раком молочной железы у женщин в зависимости от наличия наследственной отягощенности и мутаций в генах BRCA1/CHEK2. Научные результаты биомедицинских исследований. 2024; 10(1): 69-88.
16. Пономарева Т.А. Генетические варианты глобулина, связывающего половые гормоны, и гормональный профиль больных генитальным эндометриозом. Научные результаты биомедицинских исследований. 2025; 1(1): 75-90.
17. Merritt M.A., Strickler H.D., Hutson A.D., Einstein M.H., Rohan T.E., Xue X. Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer. Cancer Epidemiol Biomarkers Prev. 2021; 30(4): 719-726. https://dx.doi.org/10.1158/1055-9965.EPI-20-1613.
18. Sanderson P.A., Critchley H.O., Williams A.R., Arends M.J., Saunders P.T. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum. Reprod. Update. 2017; 23(2): 232-54. https://dx.doi.org/10.1093/humupd/dmw042
19. Hambridge H.L., Mumford S.L., Mattison D.R., Ye A., Pollack A.Z., Bloom M.S. et al. The influence of sporadic anovulation on hormone levels in ovulatory cycles. Hum. Reprod. 2013; 28(6): 1687-94. https://dx.doi.org/10.1093/humrep/det090
20. Burger H.G., Hale G.E., Dennerstein L., Robertson D.M. Cycle and hormone changes during perimenopause: the key role of ovarian function. Menopause. 2008; 15(4): 603-12. https://dx.doi.org/10.1097/gme.0b013e318174ea4d
21. Park B., Lee H., Park S., Lee E.S., Lee J.J., Lee Y. et al. Trend changes and factor analysis of endometrial hyperplasia in patients with polycystic ovarian syndrome based on the Korean National Health Insurance Database. BMC Womens Health. 2022; 22(1): 439. https://dx.doi.org/10.1186/s12905-022-02015-2
22. Meczekalski B., Pérez-Roncero G.R., López-Baena M.T., Chedraui P., Pérez-López F.R. The polycystic ovary syndrome and gynecological cancer risk. Gynecol. Endocrinol. 2020; 36(4): 289-93. https://dx.doi.org/10.1080/09513590.2020.1730794
23. Lv M., Yu J., Huang Y., Ma J., Xiang J., Wang Y. et al. Androgen signaling in uterine diseases: new insights and new targets. Biomolecules. 2022; 12(11): 1624. https://dx.doi.org/10.3390/biom12111624
24. Kuai D., Li M., He L., Li X., He Y., Liu S. et al. High fat mass index is associated with endometrial hyperplasia in polycystic ovary syndrome patients: a retrospective study. Int. J. Womens Health. 2024; 16: 2065-75. https://dx.doi.org/10.2147/IJWH.S491443
25. Lee M., Piao J., Jeon M.J. Risk factors associated with endometrial pathology in premenopausal breast cancer patients treated with tamoxifen. Yonsei Med. J. 2020; 61(4): 317-22. https://dx.doi.org/10.3349/ymj.2020.61.4.317
26. Ryu K.J., Kim M.S., Lee J.Y., Nam S., Jeong H.G., Kim T. et al. Risk of endometrial polyps, hyperplasia, carcinoma, and uterine cancer after tamoxifen treatment in premenopausal women with breast cancer. JAMA Netw. Open. 2022; 5(11): e2243951. https://dx.doi.org/10.1001/jamanetworkopen.2022.43951
27. Raut S., Bakshi N., Sharma B. Treating endometrial hyperplasia (EH) post-tamoxifen treatment in breast cancer survivors: what are our options? Med. Oncol. 2024; 41: 282. https://dx.doi.org/10.1007/s12032-024-02522-2
28. Driva T.S., Schatz C., Sobocan M., Haybaeck J. The role of mTOR and eIF signaling in benign endometrial diseases. Int. J. Mol. Sci. 2022; 23(7): 3416. https://dx.doi.org/10.3390/ijms23073416
29. Bajwa P., Nielsen S., Lombard J.M., Rassam L., Nahar P., Rueda B.R. et al. Overactive mTOR signaling leads to endometrial hyperplasia in aged women and mice. Oncotarget. 2017; 8(5): 7265-75. https://dx.doi.org/10.18632/oncotarget.13919
30. Feng L., Li J., Yang L., Zhu L., Huang X., Zhang S. et al. Tamoxifen activates Nrf2-dependent SQSTM1 transcription to promote endometrial hyperplasia. Theranostics. 2017; 7(7): 1890-1900. https://dx.doi.org/10.7150/thno.19135
31. Lam H.C., Baglini C.V., Lope A.L., Parkhitko A.A., Liu H.J., Alesi N. et al. p62/SQSTM1 Cooperates with hyperactive mTORC1 to regulate glutathione production, maintain mitochondrial integrity, and promote tumorigenesis. Cancer Res. 2017; 77(12): 3255-67. https://dx.doi.org/10.1158/0008-5472.CAN-16-2458
32. Sahoo S.S., Lombard J.M., Ius Y., O'Sullivan R., Wood L.G., Nahar P. et al. Adipose-derived VEGF-mTOR signaling promotes endometrial hyperplasia and cancer: implications for obese women. Mol. Cancer Res. 2018; 16(2): 309-21. https://dx.doi.org/10.1158/1541-7786.MCR-17-0466
33. Sumarac-Dumanovic M., Apostolovic M., Janjetovic K., Jeremic D., Popadic D., Ljubic A. et al. Downregulation of autophagy gene expression in endometria from women with polycystic ovary syndrome. Mol. Cell. Endocrinol. 2017; 440: 116-24. https://dx.doi.org/10.1016/j.mce.2016.11.009
34. Khan D., Patel R. Role of immune dysregulation in the pathogenesis of endo metrial hyperplasia. World J. Pharm. Res. 2022; 11(7): 143-58. https://dx.doi.org/10.20959/wjpr20227-24105
35. Stavropoulos A., Varras M., Philippou A., Vasilakaki T., Varra V.K., Varra F.N. et al. Immunohistochemical expression of insulin-like growth factor-1Ec in primary endometrial carcinoma: Association with PTEN, p53 and survivin expression. Oncol. Lett. 2020; 20(6): 395. https://dx.doi.org/10.3892/ol.2020.12258
36. Li S., Qu J., Wang X., Zou Q., Li C. SHP2 is involved in the occurrence, development and prognosis of cancer. Oncol. Lett. 2023; 26(3): 393. https://dx.doi.org/10.3892/ol.2023.13979
37. Pan J., Qu J., Fang W., Zhao L., Zheng W., Zhai L. et al. SHP2-triggered endothelial cell activation fuels estradiol-independent endometrial sterile inflammation. Adv. Sci. (Weinh). 2024; 11(41): e2403038. https://dx.doi.org/10.1002/advs.202403038
38. Доброхотова Ю.Э., Саламова К.К. Особенности микробиоты репродуктивного тракта у пациенток с патологией эндометрия. Российский вестник акушера-гинеколога. 2023; 23(6-2): 107 13.
39. Medina-Bastidas D., Camacho-Arroyo I., García-Gómez E. Current findings in endometrial microbiome: impact on uterine diseases. Reproduction. 2022; 163(5): R81-R96. https://dx.doi.org/10.1530/REP-21-0120.
40. Chao A., Chao A.S., Lin C.Y., Weng C.H., Wu R.C., Yeh Y.M. et al. Analysis of endometrial lavage microbiota reveals an increased relative abundance of the plastic-degrading bacteria Bacillus pseudofirmus and Stenotrophomonas rhizophila in women with endometrial cancer/endometrial hyperplasia. Front. Cell. Infect. Microbiol. 2022; 12: 1031967. https://dx.doi.org/3389/fcimb.2022.1031967
41. Ying X., Xu G., Wang H., Wang Y. An altered uterine microbiota with endometrial hyperplasia. BMC Microbiol. 2024; 24(1): 258. https://dx.doi.org/10.1186/s12866-024-03379-1
42. Han X., Zheng J., Zhang L., Zhao Z., Cheng G., Zhang W. et al. Endometrial microbial dysbiosis and metabolic alteration promote the development of endometrial cancer. Int. J. Gynaecol. Obstet. 2024; 167(2): 810-22. https://dx.doi.org/10.1002/ijgo.15718
43. Łaniewski P., Ilhan Z.E., Herbst-Kralovetz M.M. The microbiome and gynaecological cancer development, prevention and therapy. Nat. Rev. Urol. 2020; 17(4): 232-50. https://dx.doi.org/10.1038/s41585-020-0286-z
44. Baker J.M., Chase D.M., Herbst-Kralovetz M.M. Uterine microbiota: residents, tourists, or invaders? Front. Immunol. 2018; 9: 208. https://dx.doi.org/10.3389/fimmu.2018.00208
45. Dieudonne A.S., Lambrechts D., Smeets D., Belmans A., Wildiers H., Paridaens R. et al. The rs1800716 variant in CYP2D6 is associated with an increased double endometrial thickness in postmenopausal women on tamoxifen. Ann. Oncol. 2014; 25(1): 90-5. https://dx.doi.org/10.1093/annonc/mdt399
46. Demakova N.A., Altuchova O.B., Orlova V.S., Pachomov S.P., Krikun E.N. Associations of cytokines genetic polymorphisms with development of endometrial hyperplasia. Research Journal of Pharmaceutical Biological and Chemical Sciences. 2014; 5(5): 1041-5.
47. Демакова Н.А. Молекулярно-генетические характеристики пациенток с гиперплазией и полипами эндометрия. Научный результат. Медицина и фармация. 2018; 4(2): 26-39.
48. van der Putten L.J.M., van Hoof R., Tops B.B.J., Snijders M.P.L.M., van den Berg-van Erp S.H., van der Wurff A.A.M. et al. Molecular profiles of benign and (pre)malignant endometrial lesions. Carcinogenesis. 2017; 38(3): 329-35. https://dx.doi.org/10.1093/carcin/bgx008
49. Пономаренко И.В., Полоников А.В., Чурносов М.И. Ассоциация полиморфизма rs4986938 гена ESR2 с развитием гиперплазии эндометрия. Акушерство и гинекология. 2019; 4: 66-72.
50. Ponomarenko I., Reshetnikov E., Polonikov A., Sorokina I., Yermachenko A., Dvornyk V. et al. Candidate genes for age at menarche are associated with endometrial hyperplasia. Gene. 2020; 757: 144933. https://dx.doi.org/10.1016/j.gene.2020.144933
51. Фаткуллин И.Ф., Габидуллина Р.И., Смирнова Г.А., Нухбала Ф.Р., Валеева Е.В., Орлова Ю.И., Шакиров А.А. Ассоциация полиморфизма RS2414098 гена CYP19A1 с риском развития гиперплазии эндометрия. Акушерство и гинекология. 2020; 2: 125-30.
52. Алтухова О.Б., Радзинский В.Е., Полякова И.С., Чурносов М.И. Роль генов факторов роста в развитии миомы матки в сочетании с гиперплазией эндометрия. Акушерство и гинекология. 2021; 4: 104-10.
53. Алтухова О.Б., Радзинский В.Е., Полякова И.С., Сиротина С.С., Батлуцкая И.В., Орлова В.С., Ефремова О.А., Чурносов М.И. Роль генов хемокинов в развитии внутреннего генитального эндометриоза в сочетании с гиперпластическими процессами эндометрия. Акушерство и гинекология. 2022; 8: 76-84.
54. Li L., Yue P., Song Q., Yen T.T., Asaka S., Wang T.L. et al. Genome-wide mutation analysis in precancerous lesions of endometrial carcinoma. J. Pathol. 2021; 253(1): 119-28. https://dx.doi.org/10.1002/path.5566
55. Weng C.H., Wu K.Y., Wang C.J., Huang H.J., Tsai C.L., Lin C.Y. et al. Massively parallel sequencing of endometrial lavage specimens for the detection of cancer-associated mutations in atypical and non-atypical endometrial hyperplasia. Front. Med. (Lausanne). 2022; 9: 1090788. https://dx.doi.org/10.3389/fmed.2022.1090788
56. Ponomarenko M.S., Reshetnikov E.A., Churnosova M.M., Reshetnikova Y.N., Churnosov V.I., Ponomarenko I.V. Comorbidity and syntropy of benign proliferative diseases of the female reproductive system: non-genetic, genetic, and epigenetic factors (review). Research Results in Biomedicine. 2023; 9(4): 544-56. https://dx.doi.org/10.18413/2658-6533-2023-9-4-0-9
57. Tsyndrenko N.L., Lyndin M.S., Sikora K.O., Shamray A.V., Tsepochko D.G., Lyndina Yu.M. et al. Clinical-morphological and genetic characteristics of endometrial hyperplastic processes. Azerbaijan Medical Journal. 2024; 3: 75-80. https://dx.doi.org/10.34921/amj.2024.3.013
58. Russo A., Czarnecki A.A., Dean M., Modi D.A., Lantvit D.D., Hardy L. et al. PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation. Oncogene. 2018; 37(15): 1976-90. https://dx.doi.org/10.1038/s41388-017-0097-8

Поступила 07.02.2025

Принята в печать 15.05.2025